GH Research PLC (NASDAQ:GHRS – Get Free Report) fell 6.9% during trading on Tuesday after HC Wainwright lowered their price target on the stock from $65.00 to $55.00. HC Wainwright currently has a buy rating on the stock. GH Research traded as low as $17.97 and last traded at $17.7870. 15,632 shares were traded during trading, a decline of 95% from the average session volume of 305,740 shares. The stock had previously closed at $19.10.
GHRS has been the topic of several other reports. New Street Research set a $65.00 price target on shares of GH Research in a report on Monday, August 10th. Guggenheim upped their price objective on shares of GH Research from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Zacks Research raised shares of GH Research from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 13th. Wells Fargo & Company started coverage on shares of GH Research in a research report on Monday, July 27th. They issued an “overweight” rating and a $44.00 target price on the stock. Finally, Stifel Nicolaus set a $38.00 target price on shares of GH Research in a research report on Friday. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, GH Research currently has a consensus rating of “Moderate Buy” and an average target price of $43.45.
Check Out Our Latest Analysis on GH Research
Institutional Trading of GH Research
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Braidwell LP acquired a new stake in GH Research during the 2nd quarter worth approximately $5,571,000. Troluce Capital Advisors LLC grew its holdings in GH Research by 165.4% during the 1st quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock worth $13,926,000 after acquiring an additional 617,260 shares during the last quarter. Squarepoint Ops LLC acquired a new position in GH Research in the 2nd quarter valued at approximately $495,000. Renaissance Technologies LLC acquired a new position in GH Research in the 1st quarter valued at approximately $290,000. Finally, Bellevue Group AG acquired a new position in GH Research in the 3rd quarter valued at approximately $109,000. 56.90% of the stock is currently owned by institutional investors.
GH Research Stock Down 5.5%
The company’s 50 day moving average price is $22.11 and its 200-day moving average price is $21.65. The stock has a market cap of $1.22 billion, a P/E ratio of -18.66 and a beta of 1.31.
GH Research (NASDAQ:GHRS – Get Free Report) last issued its quarterly earnings results on Friday, November 13th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.13. Equities research analysts anticipate that GH Research PLC will post -1.20 earnings per share for the current year.
GH Research Company Profile
GH Research plc is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. The company is based in Dublin, Ireland, and its research centers on mebufotenin, also known as 5-MeO-DMT. Its lead investigational candidate, GH001, is an inhaled formulation being studied for treatment-resistant depression. GH Research is also developing other mebufotenin-based candidates and delivery approaches. These treatments remain investigational and are not approved for general use.
Recommended Stories
- Five stocks we like better than GH Research
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.
